GRAL · GRAIL

The thesis

GRAIL's shares are more likely to lag the S&P 500 over the next three months. A U.S. Food and Drug Administration (FDA) approval of the Galleri cancer blood test already looks largely priced in, while the commercial numbers are getting weaker. The FDA decision settles the case. The company expects it by early in the first quarter of 2027, possibly sooner, but the agency has announced no date.

The 4 November 2026 third-quarter report cut full-year Galleri revenue growth guidance to 17–21% from 22–32% and showed a lower price per test. At the UBS Global Healthcare Conference on 10 November 2026, management said it expects a broad label and expects Galleri's price to settle at $500–600 once the test is approved and payers cover it. That is below the roughly $660 average price of the third quarter.

The shares closed at $121.35 on 12 November 2026, up 78.8% over three months and well above the 200-day average of $79.18 in adjusted daily closes. That gain reflects a market that already expects approval. A broad label would meet that expectation without beating it. A narrow label, a delay or a lower price would fall short of it. The rating is low because the guidance cut and falling prices weigh on the case, while the main positive event is largely in the price.

Bullish and bearish views on GRAIL, Inc.

The bull case on GRAIL, Inc. (GRAL), in brief: management expects a broad label. The bear case: guidance was cut.

Bull case

• Management expects a broad label. At the UBS conference on 10 November 2026, GRAIL said it expects a broad label based on the data it submitted. It expects an FDA decision by early in the first quarter of 2027 and said the decision could come earlier, per Investing.com's summary of the session. Management said the main open question is whether the label includes an early-stage detection claim.
• The advisory panel voted in favour. On 23 September 2026 the FDA's Molecular and Clinical Genetics Devices Panel voted 10–0 on safety, 6–4 on effectiveness and 7–2, with one abstention, that benefits outweigh risks for adults aged 50 and older, per STAT News.
• Volume and repeat testing are growing. GRAIL sold about 56,000 Galleri tests in the third quarter, up about 24% from a year earlier. Year-to-date volume was more than 174,000, up about 36%, per the company's release of 4 November 2026. Management said on 10 November 2026 that 36% of customers had repeated the test within about 18 months, up from 29% earlier in the year.
• Payer talks have started. Management said on 10 November 2026 that commercial insurers, which had waited for FDA approval, are now in conversations with GRAIL after the panel vote. It also said employers resumed talks after pausing when the NHS-Galleri trial missed its main goal.
• Cash covers the decision window. Cash, cash equivalents and short-term securities were $788.7 million on 30 September 2026, per the third-quarter release. Management guided to a cash runway into 2029.

Bear case

• Guidance was cut. Full-year Galleri revenue growth guidance fell to 17–21% from 22–32% on 4 November 2026, per Earnings Whispers' review of the report. The shares fell 17.08% on 5 November 2026, per Investing.com as cited by Earnings Whispers, and closed at $119.13.
• Revenue missed estimates. Third-quarter sales were $37.269 million against a $44.346 million estimate, per Benzinga on 4 November 2026. Galleri revenue rose 14% from a year earlier to $37.3 million, against 24% growth for the first nine months of the year.
• Price per test and margin are falling. The average price was about $660 per test in the third quarter, down from about $700 in the second, per Earnings Whispers. Management's $500–600 target price after approval (10 November 2026) points lower again. Adjusted gross margin was 42%, down from 55% a year earlier, per the release. Management says an Illumina royalty of roughly 7% resumes in late December 2026.
• Medicare payment is years away. Management said on 10 November 2026 that it will begin coverage talks with the Centers for Medicare & Medicaid Services after approval. It targets a review of about 12 months and said Medicare payment could begin on 1 January 2029.
• The main trial missed its goal. NHS-Galleri, with 142,250 participants, did not reduce combined stage III and IV diagnoses across 12 cancers by a statistically significant amount, per Medical Daily on 8 October 2026. Fast Company reported that panelists recommended dropping "early" from the product's label.
• Losses are large and insiders sold into the rally. The third-quarter net loss was $103.6 million, and the runway guidance shortened to 2029 from 2030. SEC Form 4 filings show the chief financial officer sold 23,619 shares and the chief growth officer sold 7,873 shares at $146.39 on 5 October 2026. Chief Executive Joshua Ofman sold 20,000 shares at an average of $136.85 on 15 October 2026 under a Rule 10b5-1 trading plan.

Price setup

The shares closed at $121.35 on 12 November 2026. That is 27.1% below the 52-week intraday high of $166.47, set on 6 October 2026 shortly after the panel vote. The close sits just above the 50-day average of $120.73 and far above the 200-day average of $79.18. The 52-week closing low was $43.03 on 23 February 2026, and the reference close three months earlier was $67.87 on 14 August 2026.

After the report, the shares closed at $119.13 on 5 November 2026, rose to $128.08 on 9 November 2026 and slipped back to $121.35 by 12 November 2026. Management's comments at the UBS conference did not lift the price above the 9 November 2026 close. The 50-day average is the nearest level the case turns on. Closes well below it would show the market marking down the approval value. Closes above the October highs would show buying ahead of the decision.

Analyst targets dated after the report are on both sides of the price. Piper Sandler kept a Neutral rating and raised its target to $130 on 10 November 2026. RBC Capital kept Sector Perform with a $100 target on 5 November 2026.

Catalysts ahead

• ~31 December 2026 (est.): Illumina royalty of roughly 7% on Galleri resumes, per management. It adds a cost against an adjusted gross margin that fell to 42% in the third quarter of 2026, as per-test prices are also falling.
• ~15 January 2027 (est.): FDA decision on Galleri, expected by early first quarter 2027 per the company; no date announced. It settles the case. A broad label is what the price already reflects. A label with an early-stage claim would beat that expectation, while a narrow label, a delay or a request for more data would confirm the shares lagging.
• ~25 February 2027 (est.): Fourth-quarter and full-year 2026 results. They show whether Galleri revenue growth landed inside the cut 17–21% guidance, where per-test price and margin settled after the royalty resumed, and what 2027 guidance assumes for approval.

What would change the view

A daily close above $158.92, a level near the October peak and below the 52-week intraday high of $166.47 from 6 October 2026, which would show the shares leading the S&P 500. FDA approval with a label that includes an early-stage detection claim would also prove this call wrong.

What it trades with

GRAIL trades on its own regulatory events, so the shares move with FDA headlines, trial data, payer news and analyst notes more than with a sector index. Illumina spun GRAIL off in 2024, and royalty terms still connect the two companies. News on Medicare coverage of multi-cancer screening tests, including the Nancy Gardner Sewell multi-cancer early detection legislation, affects the long-term payment case. Management said on 10 November 2026 that this legislation sets reimbursement at $508 per test if Medicare issues a positive national coverage determination.